Contact Information

Call us at: (614) 813-8333

Clinical Therapies255 E. Main StreetColumbus, OH 43215 (map)

Learn more about Katherine M Berry

Biography

Katherine (Kate) M. Berry, PT, DPT, has worked at Nationwide Children’s Hospital since 2000. She has held positions in outpatient developmental physical therapy, multidisciplinary clinics, research, homecare and supportive roles for staff.

    “My passion lies with educating families to help their children to be the best they can and providing empathetic care with evidence based practice.”

Patient Care

Locations

Hilliard Close To Home Center with Urgent Care

Academic and Clinical Areas

Physical Therapy

Homecare Physical Therapy Team

Primary Department

Clinical Therapies

Awards, Honors & Organizations

American Physical Therapy Association Board Certified Pediatric Specialist, 2019 Member, American Physical Therapy Association Home Health Section, 2018 - Present Member, Academy of Pediatric Physical Therapy, 2017 - Present Member, Ohio Physical Therapy Association, 2017 - Present Member, American Physical Therapy Association, 1997 - Present

Research

Publications

                  Al-Zaidy S, Pickard AS, Kotha K, Alfano LN, Lowes L, Paul G, Church K, Lehman K, Sproule DM, Dabbous O, Maru B, Berry K, Arnold WD, Kissel JT, Mendell JR, Shell R. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol. 2019 Feb; 54: 179-185.

                


                  Moore U, Jacobs M, James MK, Mayhew AG, Fernandez-Torron R, Feng J, Cnaan A, Eagle M, Bettinson K, Rufibach LE, Lofra RM, Blamire AM, Carlier PG, Mittal P, Lowes LP, Alfano L, Rose K, Duong T, Berry KM, Montiel-Morillo E, Pedrosa-Hernández I, Holsten S, Sanjak M, Ashida A, Sakamoto C, Tateishi T, Yajima H, Canal A, Ollivier G, Decostre V, Mendez JB, Sánchez-Aguilera Praxedes N, Thiele S, Siener C, Shierbecker J, Florence JM, Vandevelde B, DeWolf B, Hutchence M, Gee R, Prügel J, Maron E, Hilsden H, Lochmüller H, Grieben U, Spuler S, Tesi Rocha C, Day JW, Jones KJ, Bharucha-Goebel DX, Salort-Campana E, Harms M, Pestronk A, Krause S, Schreiber-Katz O, Walter MC, Paradas C, Hogrel JY, Stojkovic T, Takeda S, Mori-Yoshimura M, Bravver E, Sparks S, Díaz-Manera J, Bello L, Semplicini C, Pegoraro E, Mendell JR, Bushby K, Straub V, Jain COS Consortium.. Assessment of disease progression in dysferlinopathy: A 1-year cohort study. Neurology. 2019 Jan 9;  

                


                  Berry KM. Evidence-Based Management of In-Toeing in Children. Clin Pediatr (Phila). 2018 Apr 1;  9922818769483.

                


                  Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, Lowes L, Alfano L, Berry K, Church K, Kissel JT, Nagendran S, L'Italien J, Sproule DM, Wells C, Cardenas JA, Heitzer MD, Kaspar A, Corcoran S, Braun L, Likhite S, Miranda C, Meyer K, Foust KD, Burghes AHM, Kaspar BK. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017 Nov 2; 377: 1713-1722.

                


                  Alfano LN, Miller NF, Berry KM, Yin H, Rolf KE, Flanigan KM, Mendell JR, Lowes LP. The 100-meter timed test: Normative data in healthy males and comparative pilot outcome data for use in Duchenne muscular dystrophy clinical trials. Neuromuscul Disord. 2017 May; 27: 452-457.

                


                  Mendell JR, Sahenk Z, Al-Zaidy S, Rodino-Klapac LR, Lowes LP, Alfano LN, Berry K, Miller N, Yalvac M, Dvorchik I, Moore-Clingenpeel M, Flanigan KM, Church K, Shontz K, Curry C, Lewis S, McColly M, Hogan MJ, Kaspar BK. Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. Mol Ther. 2017 Apr 5; 25: 870-879.

                


                  Truxal KV, Fu H, McCarty DM, McNally KA, Kunkler KL, Zumberge NA, Martin L, Aylward SC, Alfano LN, Berry KM, Lowes LP, Corridore M, McKee C, McBride KL, Flanigan KM. A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design. Mol Genet Metab. 2016 Nov; 119: 239-248.

                


                  Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, Kaye EM, Mercuri E, Eteplirsen Study Group and Telethon Foundation DMD Italian Network.. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol. 2016 Feb; 79: 257-71.

                


                  Lowes LP, Alfano LN, Crawfis R, Berry K, Yin H, Dvorchik I, Flanigan KM, Mendell JR. Reliability and validity of active-seated: An outcome in dystrophinopathy. Muscle Nerve. 2015 Sep; 52: 356-62.

                


                  Mendell JR, Sahenk Z, Malik V, Gomez AM, Flanigan KM, Lowes LP, Alfano LN, Berry K, Meadows E, Lewis S, Braun L, Shontz K, Rouhana M, Clark KR, Rosales XQ, Al-Zaidy S, Govoni A, Rodino-Klapac LR, Hogan MJ, Kaspar BK. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther. 2015 Jan; 23: 192-201.

View More Publications

Education

Date of Appointment at Nationwide Children’s Hospital: 05/30/2000

Graduate School

University of New England

Date Completed: 12/31/2017

Undergraduate School

University of Connecticut

Date Completed: 09/01/1998

Professional Experience

2000 - Present Nationwide Children’s Hospital, Physical Therapist

Contact Information

Clinical Therapies

Call us at: (614) 813-8333

                    255 E. Main StreetColumbus, OH 43215 (map)

Contact Information

Call us at: (614) 813-8333

Clinical Therapies255 E. Main StreetColumbus, OH 43215 (map)

Learn more about Katherine M Berry

Biography

Katherine (Kate) M. Berry, PT, DPT, has worked at Nationwide Children’s Hospital since 2000. She has held positions in outpatient developmental physical therapy, multidisciplinary clinics, research, homecare and supportive roles for staff.

    “My passion lies with educating families to help their children to be the best they can and providing empathetic care with evidence based practice.”

Patient Care

Locations

Hilliard Close To Home Center with Urgent Care

Academic and Clinical Areas

Physical Therapy

Homecare Physical Therapy Team

Primary Department

Clinical Therapies

Awards, Honors & Organizations

American Physical Therapy Association Board Certified Pediatric Specialist, 2019 Member, American Physical Therapy Association Home Health Section, 2018 - Present Member, Academy of Pediatric Physical Therapy, 2017 - Present Member, Ohio Physical Therapy Association, 2017 - Present Member, American Physical Therapy Association, 1997 - Present

Research

Publications

                  Al-Zaidy S, Pickard AS, Kotha K, Alfano LN, Lowes L, Paul G, Church K, Lehman K, Sproule DM, Dabbous O, Maru B, Berry K, Arnold WD, Kissel JT, Mendell JR, Shell R. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol. 2019 Feb; 54: 179-185.

                


                  Moore U, Jacobs M, James MK, Mayhew AG, Fernandez-Torron R, Feng J, Cnaan A, Eagle M, Bettinson K, Rufibach LE, Lofra RM, Blamire AM, Carlier PG, Mittal P, Lowes LP, Alfano L, Rose K, Duong T, Berry KM, Montiel-Morillo E, Pedrosa-Hernández I, Holsten S, Sanjak M, Ashida A, Sakamoto C, Tateishi T, Yajima H, Canal A, Ollivier G, Decostre V, Mendez JB, Sánchez-Aguilera Praxedes N, Thiele S, Siener C, Shierbecker J, Florence JM, Vandevelde B, DeWolf B, Hutchence M, Gee R, Prügel J, Maron E, Hilsden H, Lochmüller H, Grieben U, Spuler S, Tesi Rocha C, Day JW, Jones KJ, Bharucha-Goebel DX, Salort-Campana E, Harms M, Pestronk A, Krause S, Schreiber-Katz O, Walter MC, Paradas C, Hogrel JY, Stojkovic T, Takeda S, Mori-Yoshimura M, Bravver E, Sparks S, Díaz-Manera J, Bello L, Semplicini C, Pegoraro E, Mendell JR, Bushby K, Straub V, Jain COS Consortium.. Assessment of disease progression in dysferlinopathy: A 1-year cohort study. Neurology. 2019 Jan 9;  

                


                  Berry KM. Evidence-Based Management of In-Toeing in Children. Clin Pediatr (Phila). 2018 Apr 1;  9922818769483.

                


                  Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, Lowes L, Alfano L, Berry K, Church K, Kissel JT, Nagendran S, L'Italien J, Sproule DM, Wells C, Cardenas JA, Heitzer MD, Kaspar A, Corcoran S, Braun L, Likhite S, Miranda C, Meyer K, Foust KD, Burghes AHM, Kaspar BK. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017 Nov 2; 377: 1713-1722.

                


                  Alfano LN, Miller NF, Berry KM, Yin H, Rolf KE, Flanigan KM, Mendell JR, Lowes LP. The 100-meter timed test: Normative data in healthy males and comparative pilot outcome data for use in Duchenne muscular dystrophy clinical trials. Neuromuscul Disord. 2017 May; 27: 452-457.

                


                  Mendell JR, Sahenk Z, Al-Zaidy S, Rodino-Klapac LR, Lowes LP, Alfano LN, Berry K, Miller N, Yalvac M, Dvorchik I, Moore-Clingenpeel M, Flanigan KM, Church K, Shontz K, Curry C, Lewis S, McColly M, Hogan MJ, Kaspar BK. Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. Mol Ther. 2017 Apr 5; 25: 870-879.

                


                  Truxal KV, Fu H, McCarty DM, McNally KA, Kunkler KL, Zumberge NA, Martin L, Aylward SC, Alfano LN, Berry KM, Lowes LP, Corridore M, McKee C, McBride KL, Flanigan KM. A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design. Mol Genet Metab. 2016 Nov; 119: 239-248.

                


                  Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, Kaye EM, Mercuri E, Eteplirsen Study Group and Telethon Foundation DMD Italian Network.. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol. 2016 Feb; 79: 257-71.

                


                  Lowes LP, Alfano LN, Crawfis R, Berry K, Yin H, Dvorchik I, Flanigan KM, Mendell JR. Reliability and validity of active-seated: An outcome in dystrophinopathy. Muscle Nerve. 2015 Sep; 52: 356-62.

                


                  Mendell JR, Sahenk Z, Malik V, Gomez AM, Flanigan KM, Lowes LP, Alfano LN, Berry K, Meadows E, Lewis S, Braun L, Shontz K, Rouhana M, Clark KR, Rosales XQ, Al-Zaidy S, Govoni A, Rodino-Klapac LR, Hogan MJ, Kaspar BK. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther. 2015 Jan; 23: 192-201.

View More Publications

Education

Date of Appointment at Nationwide Children’s Hospital: 05/30/2000

Graduate School

University of New England

Date Completed: 12/31/2017

Undergraduate School

University of Connecticut

Date Completed: 09/01/1998

Professional Experience

2000 - Present Nationwide Children’s Hospital, Physical Therapist

Contact Information

Clinical Therapies

Call us at: (614) 813-8333

                    255 E. Main StreetColumbus, OH 43215 (map)

Contact Information

Call us at: (614) 813-8333

Clinical Therapies255 E. Main StreetColumbus, OH 43215 (map)

Learn more about Katherine M Berry

Contact Information

  • Call us at:
  • (614) 813-8333
  • Clinical Therapies255 E. Main StreetColumbus, OH 43215 (map)

Learn more about Katherine M Berry

Biography

Katherine (Kate) M. Berry, PT, DPT, has worked at Nationwide Children’s Hospital since 2000. She has held positions in outpatient developmental physical therapy, multidisciplinary clinics, research, homecare and supportive roles for staff.

Biography

Katherine (Kate) M. Berry, PT, DPT, has worked at Nationwide Children’s Hospital since 2000. She has held positions in outpatient developmental physical therapy, multidisciplinary clinics, research, homecare and supportive roles for staff.

Biography

Katherine (Kate) M. Berry, PT, DPT, has worked at Nationwide Children’s Hospital since 2000. She has held positions in outpatient developmental physical therapy, multidisciplinary clinics, research, homecare and supportive roles for staff.

Katherine (Kate) M. Berry, PT, DPT, has worked at Nationwide Children’s Hospital since 2000. She has held positions in outpatient developmental physical therapy, multidisciplinary clinics, research, homecare and supportive roles for staff.

Katherine (Kate) M. Berry, PT, DPT, has worked at Nationwide Children’s Hospital since 2000. She has held positions in outpatient developmental physical therapy, multidisciplinary clinics, research, homecare and supportive roles for staff.

    “My passion lies with educating families to help their children to be the best they can and providing empathetic care with evidence based practice.”

Patient Care

Locations

Hilliard Close To Home Center with Urgent Care

Patient Care

Locations

Hilliard Close To Home Center with Urgent Care

Patient Care

Locations

Hilliard Close To Home Center with Urgent Care

Locations

Hilliard Close To Home Center with Urgent Care

Locations

Hilliard Close To Home Center with Urgent Care

Locations

Hilliard Close To Home Center with Urgent Care

  • Hilliard Close To Home Center with Urgent Care

Academic and Clinical Areas

Physical Therapy

Homecare Physical Therapy Team

Primary Department

Clinical Therapies

Academic and Clinical Areas

Physical Therapy

Homecare Physical Therapy Team

Primary Department

Clinical Therapies

Academic and Clinical Areas

Physical Therapy

Homecare Physical Therapy Team

Primary Department

Clinical Therapies

Physical Therapy

Homecare Physical Therapy Team

Primary Department

Clinical Therapies

  • Physical Therapy
  • Homecare Physical Therapy Team
  • Primary Department
  • Clinical Therapies

Awards, Honors & Organizations

American Physical Therapy Association Board Certified Pediatric Specialist, 2019 Member, American Physical Therapy Association Home Health Section, 2018 - Present Member, Academy of Pediatric Physical Therapy, 2017 - Present Member, Ohio Physical Therapy Association, 2017 - Present Member, American Physical Therapy Association, 1997 - Present

Awards, Honors & Organizations

American Physical Therapy Association Board Certified Pediatric Specialist, 2019 Member, American Physical Therapy Association Home Health Section, 2018 - Present Member, Academy of Pediatric Physical Therapy, 2017 - Present Member, Ohio Physical Therapy Association, 2017 - Present Member, American Physical Therapy Association, 1997 - Present

Awards, Honors & Organizations

American Physical Therapy Association Board Certified Pediatric Specialist, 2019 Member, American Physical Therapy Association Home Health Section, 2018 - Present Member, Academy of Pediatric Physical Therapy, 2017 - Present Member, Ohio Physical Therapy Association, 2017 - Present Member, American Physical Therapy Association, 1997 - Present

American Physical Therapy Association Board Certified Pediatric Specialist, 2019 Member, American Physical Therapy Association Home Health Section, 2018 - Present Member, Academy of Pediatric Physical Therapy, 2017 - Present Member, Ohio Physical Therapy Association, 2017 - Present Member, American Physical Therapy Association, 1997 - Present

  • American Physical Therapy Association Board Certified Pediatric Specialist, 2019
  • Member, American Physical Therapy Association Home Health Section, 2018 - Present
  • Member, Academy of Pediatric Physical Therapy, 2017 - Present
  • Member, Ohio Physical Therapy Association, 2017 - Present
  • Member, American Physical Therapy Association, 1997 - Present

Research

Publications

                  Al-Zaidy S, Pickard AS, Kotha K, Alfano LN, Lowes L, Paul G, Church K, Lehman K, Sproule DM, Dabbous O, Maru B, Berry K, Arnold WD, Kissel JT, Mendell JR, Shell R. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol. 2019 Feb; 54: 179-185.

                


                  Moore U, Jacobs M, James MK, Mayhew AG, Fernandez-Torron R, Feng J, Cnaan A, Eagle M, Bettinson K, Rufibach LE, Lofra RM, Blamire AM, Carlier PG, Mittal P, Lowes LP, Alfano L, Rose K, Duong T, Berry KM, Montiel-Morillo E, Pedrosa-Hernández I, Holsten S, Sanjak M, Ashida A, Sakamoto C, Tateishi T, Yajima H, Canal A, Ollivier G, Decostre V, Mendez JB, Sánchez-Aguilera Praxedes N, Thiele S, Siener C, Shierbecker J, Florence JM, Vandevelde B, DeWolf B, Hutchence M, Gee R, Prügel J, Maron E, Hilsden H, Lochmüller H, Grieben U, Spuler S, Tesi Rocha C, Day JW, Jones KJ, Bharucha-Goebel DX, Salort-Campana E, Harms M, Pestronk A, Krause S, Schreiber-Katz O, Walter MC, Paradas C, Hogrel JY, Stojkovic T, Takeda S, Mori-Yoshimura M, Bravver E, Sparks S, Díaz-Manera J, Bello L, Semplicini C, Pegoraro E, Mendell JR, Bushby K, Straub V, Jain COS Consortium.. Assessment of disease progression in dysferlinopathy: A 1-year cohort study. Neurology. 2019 Jan 9;  

                


                  Berry KM. Evidence-Based Management of In-Toeing in Children. Clin Pediatr (Phila). 2018 Apr 1;  9922818769483.

                


                  Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, Lowes L, Alfano L, Berry K, Church K, Kissel JT, Nagendran S, L'Italien J, Sproule DM, Wells C, Cardenas JA, Heitzer MD, Kaspar A, Corcoran S, Braun L, Likhite S, Miranda C, Meyer K, Foust KD, Burghes AHM, Kaspar BK. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017 Nov 2; 377: 1713-1722.

                


                  Alfano LN, Miller NF, Berry KM, Yin H, Rolf KE, Flanigan KM, Mendell JR, Lowes LP. The 100-meter timed test: Normative data in healthy males and comparative pilot outcome data for use in Duchenne muscular dystrophy clinical trials. Neuromuscul Disord. 2017 May; 27: 452-457.

                


                  Mendell JR, Sahenk Z, Al-Zaidy S, Rodino-Klapac LR, Lowes LP, Alfano LN, Berry K, Miller N, Yalvac M, Dvorchik I, Moore-Clingenpeel M, Flanigan KM, Church K, Shontz K, Curry C, Lewis S, McColly M, Hogan MJ, Kaspar BK. Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. Mol Ther. 2017 Apr 5; 25: 870-879.

                


                  Truxal KV, Fu H, McCarty DM, McNally KA, Kunkler KL, Zumberge NA, Martin L, Aylward SC, Alfano LN, Berry KM, Lowes LP, Corridore M, McKee C, McBride KL, Flanigan KM. A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design. Mol Genet Metab. 2016 Nov; 119: 239-248.

                


                  Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, Kaye EM, Mercuri E, Eteplirsen Study Group and Telethon Foundation DMD Italian Network.. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol. 2016 Feb; 79: 257-71.

                


                  Lowes LP, Alfano LN, Crawfis R, Berry K, Yin H, Dvorchik I, Flanigan KM, Mendell JR. Reliability and validity of active-seated: An outcome in dystrophinopathy. Muscle Nerve. 2015 Sep; 52: 356-62.

                


                  Mendell JR, Sahenk Z, Malik V, Gomez AM, Flanigan KM, Lowes LP, Alfano LN, Berry K, Meadows E, Lewis S, Braun L, Shontz K, Rouhana M, Clark KR, Rosales XQ, Al-Zaidy S, Govoni A, Rodino-Klapac LR, Hogan MJ, Kaspar BK. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther. 2015 Jan; 23: 192-201.

View More Publications

Research

Publications

                  Al-Zaidy S, Pickard AS, Kotha K, Alfano LN, Lowes L, Paul G, Church K, Lehman K, Sproule DM, Dabbous O, Maru B, Berry K, Arnold WD, Kissel JT, Mendell JR, Shell R. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol. 2019 Feb; 54: 179-185.

                


                  Moore U, Jacobs M, James MK, Mayhew AG, Fernandez-Torron R, Feng J, Cnaan A, Eagle M, Bettinson K, Rufibach LE, Lofra RM, Blamire AM, Carlier PG, Mittal P, Lowes LP, Alfano L, Rose K, Duong T, Berry KM, Montiel-Morillo E, Pedrosa-Hernández I, Holsten S, Sanjak M, Ashida A, Sakamoto C, Tateishi T, Yajima H, Canal A, Ollivier G, Decostre V, Mendez JB, Sánchez-Aguilera Praxedes N, Thiele S, Siener C, Shierbecker J, Florence JM, Vandevelde B, DeWolf B, Hutchence M, Gee R, Prügel J, Maron E, Hilsden H, Lochmüller H, Grieben U, Spuler S, Tesi Rocha C, Day JW, Jones KJ, Bharucha-Goebel DX, Salort-Campana E, Harms M, Pestronk A, Krause S, Schreiber-Katz O, Walter MC, Paradas C, Hogrel JY, Stojkovic T, Takeda S, Mori-Yoshimura M, Bravver E, Sparks S, Díaz-Manera J, Bello L, Semplicini C, Pegoraro E, Mendell JR, Bushby K, Straub V, Jain COS Consortium.. Assessment of disease progression in dysferlinopathy: A 1-year cohort study. Neurology. 2019 Jan 9;  

                


                  Berry KM. Evidence-Based Management of In-Toeing in Children. Clin Pediatr (Phila). 2018 Apr 1;  9922818769483.

                


                  Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, Lowes L, Alfano L, Berry K, Church K, Kissel JT, Nagendran S, L'Italien J, Sproule DM, Wells C, Cardenas JA, Heitzer MD, Kaspar A, Corcoran S, Braun L, Likhite S, Miranda C, Meyer K, Foust KD, Burghes AHM, Kaspar BK. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017 Nov 2; 377: 1713-1722.

                


                  Alfano LN, Miller NF, Berry KM, Yin H, Rolf KE, Flanigan KM, Mendell JR, Lowes LP. The 100-meter timed test: Normative data in healthy males and comparative pilot outcome data for use in Duchenne muscular dystrophy clinical trials. Neuromuscul Disord. 2017 May; 27: 452-457.

                


                  Mendell JR, Sahenk Z, Al-Zaidy S, Rodino-Klapac LR, Lowes LP, Alfano LN, Berry K, Miller N, Yalvac M, Dvorchik I, Moore-Clingenpeel M, Flanigan KM, Church K, Shontz K, Curry C, Lewis S, McColly M, Hogan MJ, Kaspar BK. Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. Mol Ther. 2017 Apr 5; 25: 870-879.

                


                  Truxal KV, Fu H, McCarty DM, McNally KA, Kunkler KL, Zumberge NA, Martin L, Aylward SC, Alfano LN, Berry KM, Lowes LP, Corridore M, McKee C, McBride KL, Flanigan KM. A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design. Mol Genet Metab. 2016 Nov; 119: 239-248.

                


                  Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, Kaye EM, Mercuri E, Eteplirsen Study Group and Telethon Foundation DMD Italian Network.. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol. 2016 Feb; 79: 257-71.

                


                  Lowes LP, Alfano LN, Crawfis R, Berry K, Yin H, Dvorchik I, Flanigan KM, Mendell JR. Reliability and validity of active-seated: An outcome in dystrophinopathy. Muscle Nerve. 2015 Sep; 52: 356-62.

                


                  Mendell JR, Sahenk Z, Malik V, Gomez AM, Flanigan KM, Lowes LP, Alfano LN, Berry K, Meadows E, Lewis S, Braun L, Shontz K, Rouhana M, Clark KR, Rosales XQ, Al-Zaidy S, Govoni A, Rodino-Klapac LR, Hogan MJ, Kaspar BK. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther. 2015 Jan; 23: 192-201.

View More Publications

Research

Publications

                  Al-Zaidy S, Pickard AS, Kotha K, Alfano LN, Lowes L, Paul G, Church K, Lehman K, Sproule DM, Dabbous O, Maru B, Berry K, Arnold WD, Kissel JT, Mendell JR, Shell R. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol. 2019 Feb; 54: 179-185.

                


                  Moore U, Jacobs M, James MK, Mayhew AG, Fernandez-Torron R, Feng J, Cnaan A, Eagle M, Bettinson K, Rufibach LE, Lofra RM, Blamire AM, Carlier PG, Mittal P, Lowes LP, Alfano L, Rose K, Duong T, Berry KM, Montiel-Morillo E, Pedrosa-Hernández I, Holsten S, Sanjak M, Ashida A, Sakamoto C, Tateishi T, Yajima H, Canal A, Ollivier G, Decostre V, Mendez JB, Sánchez-Aguilera Praxedes N, Thiele S, Siener C, Shierbecker J, Florence JM, Vandevelde B, DeWolf B, Hutchence M, Gee R, Prügel J, Maron E, Hilsden H, Lochmüller H, Grieben U, Spuler S, Tesi Rocha C, Day JW, Jones KJ, Bharucha-Goebel DX, Salort-Campana E, Harms M, Pestronk A, Krause S, Schreiber-Katz O, Walter MC, Paradas C, Hogrel JY, Stojkovic T, Takeda S, Mori-Yoshimura M, Bravver E, Sparks S, Díaz-Manera J, Bello L, Semplicini C, Pegoraro E, Mendell JR, Bushby K, Straub V, Jain COS Consortium.. Assessment of disease progression in dysferlinopathy: A 1-year cohort study. Neurology. 2019 Jan 9;  

                


                  Berry KM. Evidence-Based Management of In-Toeing in Children. Clin Pediatr (Phila). 2018 Apr 1;  9922818769483.

                


                  Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, Lowes L, Alfano L, Berry K, Church K, Kissel JT, Nagendran S, L'Italien J, Sproule DM, Wells C, Cardenas JA, Heitzer MD, Kaspar A, Corcoran S, Braun L, Likhite S, Miranda C, Meyer K, Foust KD, Burghes AHM, Kaspar BK. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017 Nov 2; 377: 1713-1722.

                


                  Alfano LN, Miller NF, Berry KM, Yin H, Rolf KE, Flanigan KM, Mendell JR, Lowes LP. The 100-meter timed test: Normative data in healthy males and comparative pilot outcome data for use in Duchenne muscular dystrophy clinical trials. Neuromuscul Disord. 2017 May; 27: 452-457.

                


                  Mendell JR, Sahenk Z, Al-Zaidy S, Rodino-Klapac LR, Lowes LP, Alfano LN, Berry K, Miller N, Yalvac M, Dvorchik I, Moore-Clingenpeel M, Flanigan KM, Church K, Shontz K, Curry C, Lewis S, McColly M, Hogan MJ, Kaspar BK. Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. Mol Ther. 2017 Apr 5; 25: 870-879.

                


                  Truxal KV, Fu H, McCarty DM, McNally KA, Kunkler KL, Zumberge NA, Martin L, Aylward SC, Alfano LN, Berry KM, Lowes LP, Corridore M, McKee C, McBride KL, Flanigan KM. A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design. Mol Genet Metab. 2016 Nov; 119: 239-248.

                


                  Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, Kaye EM, Mercuri E, Eteplirsen Study Group and Telethon Foundation DMD Italian Network.. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol. 2016 Feb; 79: 257-71.

                


                  Lowes LP, Alfano LN, Crawfis R, Berry K, Yin H, Dvorchik I, Flanigan KM, Mendell JR. Reliability and validity of active-seated: An outcome in dystrophinopathy. Muscle Nerve. 2015 Sep; 52: 356-62.

                


                  Mendell JR, Sahenk Z, Malik V, Gomez AM, Flanigan KM, Lowes LP, Alfano LN, Berry K, Meadows E, Lewis S, Braun L, Shontz K, Rouhana M, Clark KR, Rosales XQ, Al-Zaidy S, Govoni A, Rodino-Klapac LR, Hogan MJ, Kaspar BK. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther. 2015 Jan; 23: 192-201.

View More Publications

Publications

                  Al-Zaidy S, Pickard AS, Kotha K, Alfano LN, Lowes L, Paul G, Church K, Lehman K, Sproule DM, Dabbous O, Maru B, Berry K, Arnold WD, Kissel JT, Mendell JR, Shell R. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol. 2019 Feb; 54: 179-185.

                


                  Moore U, Jacobs M, James MK, Mayhew AG, Fernandez-Torron R, Feng J, Cnaan A, Eagle M, Bettinson K, Rufibach LE, Lofra RM, Blamire AM, Carlier PG, Mittal P, Lowes LP, Alfano L, Rose K, Duong T, Berry KM, Montiel-Morillo E, Pedrosa-Hernández I, Holsten S, Sanjak M, Ashida A, Sakamoto C, Tateishi T, Yajima H, Canal A, Ollivier G, Decostre V, Mendez JB, Sánchez-Aguilera Praxedes N, Thiele S, Siener C, Shierbecker J, Florence JM, Vandevelde B, DeWolf B, Hutchence M, Gee R, Prügel J, Maron E, Hilsden H, Lochmüller H, Grieben U, Spuler S, Tesi Rocha C, Day JW, Jones KJ, Bharucha-Goebel DX, Salort-Campana E, Harms M, Pestronk A, Krause S, Schreiber-Katz O, Walter MC, Paradas C, Hogrel JY, Stojkovic T, Takeda S, Mori-Yoshimura M, Bravver E, Sparks S, Díaz-Manera J, Bello L, Semplicini C, Pegoraro E, Mendell JR, Bushby K, Straub V, Jain COS Consortium.. Assessment of disease progression in dysferlinopathy: A 1-year cohort study. Neurology. 2019 Jan 9;  

                


                  Berry KM. Evidence-Based Management of In-Toeing in Children. Clin Pediatr (Phila). 2018 Apr 1;  9922818769483.

                


                  Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, Lowes L, Alfano L, Berry K, Church K, Kissel JT, Nagendran S, L'Italien J, Sproule DM, Wells C, Cardenas JA, Heitzer MD, Kaspar A, Corcoran S, Braun L, Likhite S, Miranda C, Meyer K, Foust KD, Burghes AHM, Kaspar BK. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017 Nov 2; 377: 1713-1722.

                


                  Alfano LN, Miller NF, Berry KM, Yin H, Rolf KE, Flanigan KM, Mendell JR, Lowes LP. The 100-meter timed test: Normative data in healthy males and comparative pilot outcome data for use in Duchenne muscular dystrophy clinical trials. Neuromuscul Disord. 2017 May; 27: 452-457.

                


                  Mendell JR, Sahenk Z, Al-Zaidy S, Rodino-Klapac LR, Lowes LP, Alfano LN, Berry K, Miller N, Yalvac M, Dvorchik I, Moore-Clingenpeel M, Flanigan KM, Church K, Shontz K, Curry C, Lewis S, McColly M, Hogan MJ, Kaspar BK. Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. Mol Ther. 2017 Apr 5; 25: 870-879.

                


                  Truxal KV, Fu H, McCarty DM, McNally KA, Kunkler KL, Zumberge NA, Martin L, Aylward SC, Alfano LN, Berry KM, Lowes LP, Corridore M, McKee C, McBride KL, Flanigan KM. A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design. Mol Genet Metab. 2016 Nov; 119: 239-248.

                


                  Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, Kaye EM, Mercuri E, Eteplirsen Study Group and Telethon Foundation DMD Italian Network.. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol. 2016 Feb; 79: 257-71.

                


                  Lowes LP, Alfano LN, Crawfis R, Berry K, Yin H, Dvorchik I, Flanigan KM, Mendell JR. Reliability and validity of active-seated: An outcome in dystrophinopathy. Muscle Nerve. 2015 Sep; 52: 356-62.

                


                  Mendell JR, Sahenk Z, Malik V, Gomez AM, Flanigan KM, Lowes LP, Alfano LN, Berry K, Meadows E, Lewis S, Braun L, Shontz K, Rouhana M, Clark KR, Rosales XQ, Al-Zaidy S, Govoni A, Rodino-Klapac LR, Hogan MJ, Kaspar BK. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther. 2015 Jan; 23: 192-201.

View More Publications

                  Al-Zaidy S, Pickard AS, Kotha K, Alfano LN, Lowes L, Paul G, Church K, Lehman K, Sproule DM, Dabbous O, Maru B, Berry K, Arnold WD, Kissel JT, Mendell JR, Shell R. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol. 2019 Feb; 54: 179-185.

                


                  Moore U, Jacobs M, James MK, Mayhew AG, Fernandez-Torron R, Feng J, Cnaan A, Eagle M, Bettinson K, Rufibach LE, Lofra RM, Blamire AM, Carlier PG, Mittal P, Lowes LP, Alfano L, Rose K, Duong T, Berry KM, Montiel-Morillo E, Pedrosa-Hernández I, Holsten S, Sanjak M, Ashida A, Sakamoto C, Tateishi T, Yajima H, Canal A, Ollivier G, Decostre V, Mendez JB, Sánchez-Aguilera Praxedes N, Thiele S, Siener C, Shierbecker J, Florence JM, Vandevelde B, DeWolf B, Hutchence M, Gee R, Prügel J, Maron E, Hilsden H, Lochmüller H, Grieben U, Spuler S, Tesi Rocha C, Day JW, Jones KJ, Bharucha-Goebel DX, Salort-Campana E, Harms M, Pestronk A, Krause S, Schreiber-Katz O, Walter MC, Paradas C, Hogrel JY, Stojkovic T, Takeda S, Mori-Yoshimura M, Bravver E, Sparks S, Díaz-Manera J, Bello L, Semplicini C, Pegoraro E, Mendell JR, Bushby K, Straub V, Jain COS Consortium.. Assessment of disease progression in dysferlinopathy: A 1-year cohort study. Neurology. 2019 Jan 9;  

                


                  Berry KM. Evidence-Based Management of In-Toeing in Children. Clin Pediatr (Phila). 2018 Apr 1;  9922818769483.

                


                  Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, Lowes L, Alfano L, Berry K, Church K, Kissel JT, Nagendran S, L'Italien J, Sproule DM, Wells C, Cardenas JA, Heitzer MD, Kaspar A, Corcoran S, Braun L, Likhite S, Miranda C, Meyer K, Foust KD, Burghes AHM, Kaspar BK. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017 Nov 2; 377: 1713-1722.

                


                  Alfano LN, Miller NF, Berry KM, Yin H, Rolf KE, Flanigan KM, Mendell JR, Lowes LP. The 100-meter timed test: Normative data in healthy males and comparative pilot outcome data for use in Duchenne muscular dystrophy clinical trials. Neuromuscul Disord. 2017 May; 27: 452-457.

                


                  Mendell JR, Sahenk Z, Al-Zaidy S, Rodino-Klapac LR, Lowes LP, Alfano LN, Berry K, Miller N, Yalvac M, Dvorchik I, Moore-Clingenpeel M, Flanigan KM, Church K, Shontz K, Curry C, Lewis S, McColly M, Hogan MJ, Kaspar BK. Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. Mol Ther. 2017 Apr 5; 25: 870-879.

                


                  Truxal KV, Fu H, McCarty DM, McNally KA, Kunkler KL, Zumberge NA, Martin L, Aylward SC, Alfano LN, Berry KM, Lowes LP, Corridore M, McKee C, McBride KL, Flanigan KM. A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design. Mol Genet Metab. 2016 Nov; 119: 239-248.

                


                  Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, Kaye EM, Mercuri E, Eteplirsen Study Group and Telethon Foundation DMD Italian Network.. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol. 2016 Feb; 79: 257-71.

                


                  Lowes LP, Alfano LN, Crawfis R, Berry K, Yin H, Dvorchik I, Flanigan KM, Mendell JR. Reliability and validity of active-seated: An outcome in dystrophinopathy. Muscle Nerve. 2015 Sep; 52: 356-62.

                


                  Mendell JR, Sahenk Z, Malik V, Gomez AM, Flanigan KM, Lowes LP, Alfano LN, Berry K, Meadows E, Lewis S, Braun L, Shontz K, Rouhana M, Clark KR, Rosales XQ, Al-Zaidy S, Govoni A, Rodino-Klapac LR, Hogan MJ, Kaspar BK. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther. 2015 Jan; 23: 192-201.

View More Publications

  • Al-Zaidy S, Pickard AS, Kotha K, Alfano LN, Lowes L, Paul G, Church K, Lehman K, Sproule DM, Dabbous O, Maru B, Berry K, Arnold WD, Kissel JT, Mendell JR, Shell R. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol. 2019 Feb; 54: 179-185.
  • Moore U, Jacobs M, James MK, Mayhew AG, Fernandez-Torron R, Feng J, Cnaan A, Eagle M, Bettinson K, Rufibach LE, Lofra RM, Blamire AM, Carlier PG, Mittal P, Lowes LP, Alfano L, Rose K, Duong T, Berry KM, Montiel-Morillo E, Pedrosa-Hernández I, Holsten S, Sanjak M, Ashida A, Sakamoto C, Tateishi T, Yajima H, Canal A, Ollivier G, Decostre V, Mendez JB, Sánchez-Aguilera Praxedes N, Thiele S, Siener C, Shierbecker J, Florence JM, Vandevelde B, DeWolf B, Hutchence M, Gee R, Prügel J, Maron E, Hilsden H, Lochmüller H, Grieben U, Spuler S, Tesi Rocha C, Day JW, Jones KJ, Bharucha-Goebel DX, Salort-Campana E, Harms M, Pestronk A, Krause S, Schreiber-Katz O, Walter MC, Paradas C, Hogrel JY, Stojkovic T, Takeda S, Mori-Yoshimura M, Bravver E, Sparks S, Díaz-Manera J, Bello L, Semplicini C, Pegoraro E, Mendell JR, Bushby K, Straub V, Jain COS Consortium.. Assessment of disease progression in dysferlinopathy: A 1-year cohort study. Neurology. 2019 Jan 9;
  • Berry KM. Evidence-Based Management of In-Toeing in Children. Clin Pediatr (Phila). 2018 Apr 1; 9922818769483.
  • Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, Lowes L, Alfano L, Berry K, Church K, Kissel JT, Nagendran S, L’Italien J, Sproule DM, Wells C, Cardenas JA, Heitzer MD, Kaspar A, Corcoran S, Braun L, Likhite S, Miranda C, Meyer K, Foust KD, Burghes AHM, Kaspar BK. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017 Nov 2; 377: 1713-1722.
  • Alfano LN, Miller NF, Berry KM, Yin H, Rolf KE, Flanigan KM, Mendell JR, Lowes LP. The 100-meter timed test: Normative data in healthy males and comparative pilot outcome data for use in Duchenne muscular dystrophy clinical trials. Neuromuscul Disord. 2017 May; 27: 452-457.
  • Mendell JR, Sahenk Z, Al-Zaidy S, Rodino-Klapac LR, Lowes LP, Alfano LN, Berry K, Miller N, Yalvac M, Dvorchik I, Moore-Clingenpeel M, Flanigan KM, Church K, Shontz K, Curry C, Lewis S, McColly M, Hogan MJ, Kaspar BK. Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. Mol Ther. 2017 Apr 5; 25: 870-879.
  • Truxal KV, Fu H, McCarty DM, McNally KA, Kunkler KL, Zumberge NA, Martin L, Aylward SC, Alfano LN, Berry KM, Lowes LP, Corridore M, McKee C, McBride KL, Flanigan KM. A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design. Mol Genet Metab. 2016 Nov; 119: 239-248.
  • Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, Kaye EM, Mercuri E, Eteplirsen Study Group and Telethon Foundation DMD Italian Network.. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol. 2016 Feb; 79: 257-71.
  • Lowes LP, Alfano LN, Crawfis R, Berry K, Yin H, Dvorchik I, Flanigan KM, Mendell JR. Reliability and validity of active-seated: An outcome in dystrophinopathy. Muscle Nerve. 2015 Sep; 52: 356-62.
  • Mendell JR, Sahenk Z, Malik V, Gomez AM, Flanigan KM, Lowes LP, Alfano LN, Berry K, Meadows E, Lewis S, Braun L, Shontz K, Rouhana M, Clark KR, Rosales XQ, Al-Zaidy S, Govoni A, Rodino-Klapac LR, Hogan MJ, Kaspar BK. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther. 2015 Jan; 23: 192-201.

Education

Date of Appointment at Nationwide Children’s Hospital: 05/30/2000

Graduate School

University of New England

Date Completed: 12/31/2017

Undergraduate School

University of Connecticut

Date Completed: 09/01/1998

Education

Date of Appointment at Nationwide Children’s Hospital: 05/30/2000

Graduate School

University of New England

Date Completed: 12/31/2017

Undergraduate School

University of Connecticut

Date Completed: 09/01/1998

Education

Date of Appointment at Nationwide Children’s Hospital: 05/30/2000

Graduate School

University of New England

Date Completed: 12/31/2017

Undergraduate School

University of Connecticut

Date Completed: 09/01/1998

Date of Appointment at Nationwide Children’s Hospital: 05/30/2000

Graduate School

University of New England

Date Completed: 12/31/2017

Undergraduate School

University of Connecticut

Date Completed: 09/01/1998

Date of Appointment at Nationwide Children’s Hospital: 05/30/2000

Graduate School

University of New England

Date Completed: 12/31/2017

Undergraduate School

University of Connecticut

Date Completed: 09/01/1998

Professional Experience

2000 - Present Nationwide Children’s Hospital, Physical Therapist

Professional Experience

2000 - Present Nationwide Children’s Hospital, Physical Therapist

Professional Experience

2000 - Present Nationwide Children’s Hospital, Physical Therapist

2000 - Present Nationwide Children’s Hospital, Physical Therapist

2000 - Present Nationwide Children’s Hospital, Physical Therapist

Contact Information

Clinical Therapies

Call us at: (614) 813-8333

                    255 E. Main StreetColumbus, OH 43215 (map)

Contact Information

Clinical Therapies

Call us at: (614) 813-8333

                    255 E. Main StreetColumbus, OH 43215 (map)

Contact Information

Clinical Therapies

Call us at: (614) 813-8333

                    255 E. Main StreetColumbus, OH 43215 (map)

Clinical Therapies

Call us at: (614) 813-8333

                    255 E. Main StreetColumbus, OH 43215 (map)

Call us at: (614) 813-8333

                    255 E. Main StreetColumbus, OH 43215 (map)

Call us at: (614) 813-8333

                    255 E. Main StreetColumbus, OH 43215 (map)
  • Call us at:
  • (614) 813-8333
  • 255 E. Main StreetColumbus, OH 43215 (map)